A Different Approach
SignalChem Lifesciences has built a world-class kinase technology platform that is generating new, patient-specific, drug candidates for the targeted treatment of cancer and other diseases.
Kinase Therapy. Better Outcomes
SignalChem Lifesciences (“SLC”) discovers and develops drug candidates using a personalized medicine approach. We identify patients with a specific kinase defect and then select a relevant targeted therapy against the defective kinase. SLC’s development process selects the most relevant kinase targets for drug development and identifies the best compound from our kinase specific chemical library. This ensures best-in-class potency and superior selectivity; yielding highly effective drug candidates with greatly reduced side effects. Our approach has the potential to provide a much more effective therapy and allows SLC to apply the therapy to only those patients who are most likely to receive a meaningful clinical benefit.